[1] M. G. Guzman, M. Alvarez and S. B. Halstead, Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Archives of virology 158(7) (2013) 1445-59.
[3] J. A. Ayukekbong, O. G. Oyero, S. E. Nnukwu, H. N. Mesumbe, C. N. Fobisong, Value of routine dengue diagnosis in endemic countries. World journal of virology, 6(1) (2017) 9.
[4] K. S. Vannice, A. Wilder-Smith, A. D. Barrett, K Carrijo, M. Cavaleri, A. de Silva, A. P. Durbin, T. Endy, E. Harris, B. L. Innis, and L. C. Katzelnick, Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. Vaccine 36(24) (2018) 3411-3417.
[5] A. L. Rothman, C. L. Medin, H. Friberg and J. R. Currier, Immunopathogenesis versus protection in dengue virus infections. Current tropical medicine reports, 1(1) (2014) 13-20.
[6] Y. Yao, T. Huo, Y. L. Lin, S. Nie, F. Wu, Y. Hua, J. Wu, A. R. Kneubehl, M. B. Vogt, R. Rico-Hesse and Y. Song, Discovery, X-ray crystallography and antiviral activity of allosteric inhibitors of flavivirus NS2B-NS3 protease. Journal of the American Chemical Society, 141(17) (2019) 6832-6836.
[7] H. Malet, N. Massé, B. Selisko, J. L. Romette, K. Alvarez, J. C. Guillemot, H. Tolou, T. L. Yap, S. G. Vasudevan, J. Lescar and Canard, The flavivirus polymerase as a target for drug discovery. Antiviral research, 80(1) (2008) 23-35.
[8] S. P. Lim, Dengue drug discovery: Progress, challenges and outlook. Antiviral Research, 163(2019) 156-78.
[9] S. P. Lim, C. G. Noble and P. Y. Shi, The dengue virus NS5 protein as a target for drug discovery. Antiviral research, 119 (2015) 57-67.
[10] C. G. Noble, Y. L. Chen, H. Dong, F. Gu, S. P. Lim, W. Schul, Q. Y. Wang and P. Y. Shi Strategies for development of dengue virus inhibitors. Antiviral research, 85(3) (2010) 450-62.
[11] G. R. Medigeshi, R. Kumar, E. Dhamija, T. Agrawal and M. Kar, N-Desmethylclozapine, fluoxetine, and salmeterol inhibit postentry stages of the dengue virus life cycle. Antimicrobial agents and chemotherapy, 60(11) (2016) 6709-18.
[12] C. Nitsche, S. Holloway, T. Schirmeister and C. D. Klein, Biochemistry and medicinal chemistry of the dengue virus protease. Chemical reviews, 114(22) (2014) 11348-81.
[13] J. Joubert, E. B. Foxen and S. F. Malan, Microwave Optimized Synthesis of N-(adamantan-1-yl)-4-[(adamantan-1-yl)-sulfamoyl] benzamide and Its Derivatives for Anti-Dengue Virus Activity. Molecules, 23(7) (2018) 1678.
[14] C. Nitsche, L. Zhang, L. F. Weigel, J. Schilz, D. Graf, R. Bartenschlager, R. Hilgenfeld, C. D. Klein, Peptide–boronic acid inhibitors of flaviviral proteases: medicinal chemistry and structural biology. Journal of medicinal chemistry, 60(1) (2017) 511-6.
[15] J. C. Madden, M. T. Cronin, Structure-based methods for the prediction of drug metabolism. Expert opinion on drug metabolism & toxicology, 2(4) (2006) 545-57.
[16] D. Lu, J. Liu, Y. Zhang, F. Liu, L. Zeng, R. Peng, L. Yang, H. Ying, W. Tang, W. Chen, J. Zuo, Discovery and optimization of phthalazinone derivatives as a new class of potent dengue virus inhibitors. European Journal of Medicinal Chemistry, 145 (2018) 328-37.
[17] W. J. Hehre and W. W. Huang, Chemistry with computation: an introduction to SPARTAN. Wavefunction. Inc, Irvine (1995).
[18] O. Trott and A. J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry, 31(2) (2010) 455-46.
[19] A. Daina, O. Michielin, V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports 7 (2017) 42717.
[20] C. H. Tseng, C. K. Lin, Y. L. Chen, C. Y. Hsu, H. N. Wu, C. K.Tseng and J. C. Lee, Synthesis, antiproliferative and anti-dengue virus evaluations of 2-aroyl-3-arylquinoline derivatives. European Journal of Medicinal Chemistry 79 (2018) 66-76.
[21] J. C. Lee, C. K. Tseng, C. K. Lin, and C. H. Tseng, Discovery of novel diarylpyrazolylquinoline derivatives as potent anti-dengue virus agents. European Journal of Medicinal Chemistry, 141(2017) 282-92.
[22] S. N. Adawara, G. A. Shallangwa, P. A. Mamza and A. Ibrahim, Molecular docking and QSAR theoretical model for prediction of phthalazinone derivatives as new class of potent dengue virus inhibitors. Beni-Suef University Journal of Basic and Applied Sciences, 9(1) (2020) 1-17.
[23] S. Tian, J. Wang, Li Y, D. Li, L. Xu and T. Hou, The application of in silico drug-likeness predictions in pharmaceutical research. Advanced drug delivery reviews, 86 (2015) 2-10.
[24] S. A. Siadati, N. Nami and M. R. Zardoost, A DFT Study of Solvent Effects on the Cycloaddition of Norbornadiene and 3, 4–Dihydroisoquinoline-N-Oxide. Progress in Reaction Kinetics and Mechanism, 36(3) (2011) 252-258.
[25] M. R. Zardoost and S. A. Siadati, A DFT study on the effect of functional groups on the formation kinetics of 1, 2, 3-triazolo-1, 4-benzoxazine via intramolecular 1, 3-dipolar cycloaddition. Progress in Reaction Kinetics and Mechanism, 38(2) (2013) 191-196.
[26] M. R Zardoost, S. A. Siadati, B. G. and Oghani, A DFT study on the 1, 3-dipolar cycloaddition of benzonitrile oxide and N-ethylmaleimide. Progress in Reaction Kinetics and Mechanism, 38(3) (2013) 316-322.
[27] C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, 23(1-3) (1997) 3-25.
[28] D. F. Veber, S. R. Johnson, H. Y. Cheng, B. R. Smith, K. W. Ward and K. D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates. Journal of medicinal chemistry 45(12) (2002) 2615-23.
[29] P. C. Trippier, selecting good ‘drug-like’ properties to optimize small molecule blood-brain barrier penetration. Current medicinal chemistry, 23(14) (2016) 1392-407.
[30] D. J. Triggle and J. B. Taylor, Comprehensive Medicinal Chemistry II, vol. 7 (2006) (Elsevier, Amsterdam).
[31] A. Daina and V. Zoete, A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMed-Chem, 11(11) (2016) 1117–1121.
[32] F. Montanari, and G. F. Ecker, Prediction of drug–ABC-transporter interaction—Recent advances and future challenges. Advanced drug delivery reviews, 86 (2015) 17-26.
[33] G. Szakács, A. Váradi, C. Özvegy-Laczka, and B. Sarkadi, The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox). Drug discovery today, 13(9-10) (2008) 379-93.
[34] K. Tsaioun and S. A. Kates, ADMET for medicinal chemists: a practical guide. John Wiley & Sons, (2011).
[35] P. F. Hollenberg, Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug metabolism reviews, 34(1-2) (2002) 17-35.
[36] S. M. Huang, J.M. Strong, L. Zhang, K. S. Reynolds, S. Nallani, R. Temple, S. Abraham, S. A. Habet, R. K. Baweja, G. J. Burckart and S. Chung, New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. The Journal of clinical pharmacology, 48(6) (2008) 662-70.
[37] R. A.van Waterschoot and A. H. Schinkel, A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacological reviews, 63(2) (2011) 390-410